Private Advisor Group LLC Invests $575,000 in Insmed Incorporated (NASDAQ:INSM)

Private Advisor Group LLC purchased a new position in Insmed Incorporated (NASDAQ:INSM) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 8,577 shares of the biopharmaceutical company’s stock, valued at approximately $575,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of INSM. EntryPoint Capital LLC acquired a new stake in shares of Insmed during the first quarter valued at approximately $33,000. Fidelis Capital Partners LLC purchased a new stake in shares of Insmed in the first quarter valued at $34,000. First Horizon Advisors Inc. boosted its position in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares during the period. Headlands Technologies LLC purchased a new position in shares of Insmed during the first quarter valued at $59,000. Finally, CWM LLC raised its position in Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 155 shares during the period.

Insider Buying and Selling

In other news, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares of the company’s stock, valued at $5,045,093.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at $7,951,559.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the transaction, the insider now owns 67,856 shares in the company, valued at $5,045,093.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,882 shares of company stock valued at $5,765,446. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

INSM has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Thursday, August 29th. Evercore ISI upped their price objective on shares of Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a research note on Friday, June 21st. Morgan Stanley increased their target price on shares of Insmed from $60.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 12th. TD Cowen boosted their price target on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Mizuho increased their price objective on Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, June 7th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and an average target price of $79.19.

Insmed Trading Down 0.5 %

Shares of INSM stock opened at $72.87 on Thursday. The business’s 50 day moving average is $74.77 and its two-hundred day moving average is $51.39. The company has a quick ratio of 2.53, a current ratio of 2.71 and a debt-to-equity ratio of 25.05. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a market cap of $10.83 billion, a PE ratio of -13.93 and a beta of 1.11.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analysts’ expectations of $87.95 million. During the same quarter in the previous year, the business earned ($1.78) EPS. Insmed’s revenue for the quarter was up 17.0% on a year-over-year basis. Equities analysts predict that Insmed Incorporated will post -5.42 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.